Enregistrement :
36
de
40
(2023-12-21
à
2024-01-08)
Politique ou Programme
Communications regarding access to and approval of medicines addressing the growing public health threat of antimicrobial resistance.
Communications regarding the design and implementation of the federal Drugs for Rare Diseases strategy.
Communications regarding the value assessment of new medicines by the Canadian Drug Agency (CDA) and the design of proposed new work streams, insofar as the federal government is a funder and holds a seat on the Board of Directors.
Communications with Health Canada regarding guidelines for pediatric action plans.
Communications with Health Canada regarding the application of its nitrosamine guidelines.
Engagement with Health Canada’s Regulatory Operations & Enforcement branch regarding supply chain resilience & integrity; mitigating and alleviating drug shortages.
Federal Government Non Insured Health Benefits program with respect to reimbursement of a prescription medicine and changes in type of reimbursement
Innovation, Science and Economic Development (ISED)'s Biomanufacturing and Life Sciences Strategy, pertaining to growth and development of the life sciences industry in Canada.
Patented Medicine Prices Review Board (PMPRB) Guidelines with regard to prices charged by Rights Holders for patented medicines sold in Canada.
Public Health Agency of Canada, regarding the federal response to the hepatitis C virus.
The pan Canadian Pharmaceutical Alliance (pCPA) with respect to public formulary listing of new medicines, insofar as the federal government is a participating jurisdiction and holds a seat on the Board of Directors.
Politique ou Programme, Proposition législative, Projet de loi ou résolution, Règlement
Communications regarding national pharmacare legislation, regulations, policies or programs.
Politique ou Programme, Règlement
Communications regarding Health Canada's Regulatory Innovation Agenda regarding proposed regulatory amendments and guidelines to enable agile licensing of drugs and medical devices.
Communications regarding intellectual property protection of prescription drugs, including the Patent Act, the Patented Medicines Regulations, the Patented Medicine Notice of Compliance (PMNOC) Regulations, the Patent Term Adjustment regime and Health Canada’s Data Protection regime.
Communications with Health Canada regarding modernization of clinical trials regulations, including diversity and inclusivity of clinical trials.
Communications with Health Canada regarding the evolution of the regulatory framework to address advanced therapeutic products.
Communications with Heath Canada regarding modernization of the medical devices regulatory framework.